Abatacept

Abatacept, sold under the brand name Orencia, is a drug. It is used to treat autoimmune diseases like rheumatoid arthritis, by interfering with the immune activity of T cells. It is a modified antibody.

Abatacept
Systematic (IUPAC) name
?
Identifiers
CAS number	332348-12-6
ATC code	L04AA24
PubChem	?
DrugBank	DB01281
ChemSpider	none
Chemical data
Formula	C3498H5458Template:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxN922Template:OrganicBoxO1090Template:OrganicBoxTemplate:OrganicBoxS32Template:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBoxTemplate:OrganicBox
Mol. mass	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	13.1 days
Excretion	?
Therapeutic considerations
Licence data	EU EMEA:link, US Daily Med:link
Pregnancy cat.	C(AU)
Legal status	POM(UK) ℞-only(US)
Routes	Intravenous, subcutaneous

Abatacept is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4. In order for a T cell to be activated and produce an immune response, an antigen-presenting cell must present two signals to the T cell.